Debunking the debulking in glioma surgery
Neuro-Oncology Practice · 13.01.2023 · 10 (1) · 104-105
DOI: 10.1093/nop/npac083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Practice, online erschienen am 26.10.2022. Verfasst von Antonio Di Ieva. Beteiligte Einrichtung: Faculty of Medicine, Health and Human Sciences, Macquarie Medical School, & Computational NeuroSurgery (CNS) Lab, Macquarie University, Sydney, New S…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The recent paper by Gerritsen et al.1 in The Lancet Oncology brings new evidence on the role of functional mapping and neuromonitoring for the surgical treatment of patients affected by glioblastoma. In a nutshell, the propensity score-matched analysis of this cohort study has shown that awake craniotomy is useful to improve postoperative outcomes when compared to asleep resection, at least in patients younger than 70 years old, and to prevent late neurological morbidity in patients ≥70 years old. A survival benefit was eventually found as a result of the synergistic effect between greater extent of resection allowed by awake surgery and the heightened sensitivity of MGMT (Methyl Guanine Methyl Transferase) methylated tumors to adjuvant therapy.1 The message of the research has also been emphasized further by Krieg’s comment2 on awake craniotomy as a mandatory part of the armamentarium of surgical neuro-oncologists. If on one hand over the last years there has been an increasing number of high quality research and publications on the role of maximal and supramaximal resection in low-grade glioma as well as glioblastoma to preserve function and improve survival,3 on the other hand the reality is that unfortunately many neurosurgeons and multidisciplinary teams around the world continue to consider glioblastoma as a disease to be essentially treated by means of radiochemotherapy. This leaves a marginal role to surgery that is often aimed to provide a surgical sample for biopsy or to “debulk” the lesion, that is, performing partial resections of the tumor bulk, often even performed more in the central necrotic part of the tumor rather than on its enhancing edges. This might sound unreal nowadays, but it is confirmed by the multitude of patients looking for second opinions after having undergone operations of biopsy or minimal debulking of their glioma. Tumor debulking (ie, partial resection) might have a role in improving quality of life and lowering steroid requirements, but a limited resection should not be aimed a priori, above all if related to lack of training and expertise by the neurosurgeon in the subfield of surgical neuro-oncology. This is a well-known reality to neurohospitalists dealing with patients affected by glioma, hiding in the penumbra of the spotlights of peer-reviewed publications and scientific presentations.
Autor:innen und Institutionen
- Faculty of Medicine, Health and Human Sciences, Macquarie Medical School, & Computational NeuroSurgery (CNS) Lab, Macquarie University, Sydney, New South Wales, Australia.
ORCID-Profile: Antonio Di Ieva
Zitieren
APA
Di Ieva, A. (2023). Debunking the debulking in glioma surgery. Neuro-Oncology Practice, 10(1), 104-105. https://doi.org/10.1093/nop/npac083
Vancouver
Di Ieva A. Debunking the debulking in glioma surgery. Neuro-Oncology Practice. 2023;10(1):104-105. doi:10.1093/nop/npac083
BibTeX
@article{DiIeva2023,
author = {Di Ieva, Antonio},
title = {Debunking the debulking in glioma surgery},
journal = {Neuro-Oncology Practice},
year = {2023},
volume = {10},
number = {1},
pages = {104--105},
doi = {10.1093/nop/npac083}
}
EUVIMED